Anna Bratulic

1 month ago | cyberera.com.ng | Anna Bratulic

By Anna BratulicJohnson & Johnson’s icotrokinra  met the primary endpoint of a Phase IIb ulcerative colitis (UC) study, building on its recent success in psoriasis. The IL-23-blocking oral peptide could also boost the company’s efforts to stay ahead in immunology as Stelara (ustekinumab) stares down biosimilar competition.

1 month ago | cyberera.com.ng | Anna Bratulic

By Anna BratulicTempus AI announced the acquisition of Deep 6 AI, a precision research platform that specialises in clinical trial matching through AI analysis of electronic medical records (EMRs). The purchase marks the latest in Tempus’ deal spree following its IPO last June that raised US$410.7 million.

1 month ago | cyberera.com.ng | Anna Bratulic

By Anna BratulicJohnson & Johnson’s icotrokinra  met the primary endpoint of a Phase IIb ulcerative colitis (UC) study, building on its recent success in psoriasis. The IL-23-blocking oral peptide could also boost the company’s efforts to stay ahead in immunology as Stelara (ustekinumab) stares down biosimilar competition.

1 month ago | cyberera.com.ng | Anna Bratulic

By Anna BratulicBluebird bio is set to go private in a buyout by private equity firms Carlyle and SK Capital Partners, ending its turbulent run as a public company amid ongoing financial struggles. Once seen as a trailblazer in the gene therapy space, bluebird has faced mounting challenges, including shuttering its European operations after failed pricing talks for its products, and a warning about its financial viability three years ago.

1 month ago | cyberera.com.ng | Anna Bratulic

By Anna BratulicIncyte is making a hefty bet on AI-based drug discovery, teaming up with biotech startup Genesis Therapeutics in a deal that could be worth a total of over US$900 million. The goal? To use Genesis’ AI platform to design new small-molecule drugs faster and more effectively. “AI has the potential to redefine how we discover small-molecule medicines, and our team is at the forefront of this revolution,” Genesis CEO Evan Feinberg said in a release Thursday.